LANGER DENNIS
- SEC CIK
- 0001274225
Latest role at each company
- QNRX Quoin Pharmaceuticals Ltd.Directoras of Aug 28, 2026
- MYGN MYRIAD GENETICS INCDirectoras of Jun 30, 2022
- ERNA Ernexa Therapeutics Inc.Directoras of Dec 10, 2021
Trades
Every Form 4 that lists LANGER DENNIS as a reporting owner, including filings made jointly with others. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
| Company | Filed (ET) | Trade date | Insider | Transaction | Shares | Avg price | Value | Shares after | Holding change | Filing |
|---|---|---|---|---|---|---|---|---|---|---|
| QNRXQuoin Pharmaceuticals Ltd. | Oct 15, 2025 | Oct 14, 2025 | LANGER DENNISDirector | PPurchaseADSs | +15.15K | $8.49 | +$128.64K | 15.15K | +1,515,200.0% | SEC |
| QNRXQuoin Pharmaceuticals Ltd. | Oct 15, 2025 | Oct 14, 2025 | LANGER DENNISDirector | PPurchaseADS · Derivative | +60.61K | – | – | 15.15K | – | SEC |
| QNRXQuoin Pharmaceuticals Ltd. | Jun 10, 2024 | Jun 7, 2024 | LANGER DENNISDirector | SSaleOrdinary Shares | −297 | $0.73 | −$216.81 | 53 | −84.9% | SEC |
| MYGNMYRIAD GENETICS INC | Aug 5, 2021 | Aug 3, 2021 | LANGER DENNISDirector | SSaleCommon Stock | −30K | $34.75 | −$1.04M | 89.53K | −25.1% | SEC |